Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Biotricity has launched HeartSecure, a direct-to-consumer cardiac screening service, now available for online purchase. Addressing the leading cause of death, heart disease, HeartSecure offers immediate, at-home screening results, bypassing the traditional wait times for appointments and test results. Key benefits include instant results, accessibility, and affordability. Dr. Waqaas Al-Siddiq, Founder and CEO, highlights HeartSecure's role in democratizing cardiac health and creating new revenue streams. This innovation aligns with the expanding home healthcare market, expected to grow from $250 billion in 2023 to $383 billion by 2028.
- Launch of HeartSecure providing immediate, at-home cardiac screening results.
- HeartSecure eliminates long wait times for appointments and results.
- Affordable option for comprehensive cardiac monitoring.
- Potential new revenue streams for Biotricity through direct-to-consumer sales in an expanding market.
- None.
Insights
HeartSecure, the latest offering from Biotricity, directly aligns with a significant market demand for accessible and timely healthcare solutions. The ability to conduct immediate, at-home cardiac screenings is particularly revolutionary given the high incidence of cardiovascular diseases globally. Traditionally, the delay in cardiac screening results could lead to critical health interventions being postponed. By offering instant results, HeartSecure could potentially lower the risk of adverse cardiac events, thereby improving patient outcomes.
Affordability is another selling point that cannot be undermined. The lower barrier to entry means more individuals, especially those in underserved areas, can access essential cardiac care. This democratization of healthcare is not just a marketing statement but a real-world impact that could shift the landscape of cardiac health management.
From a clinical perspective, the continuous monitoring and immediate results also allow for more dynamic patient management, where healthcare providers could intervene promptly if an abnormality is detected. The innovation aligns with current healthcare trends focusing on preventive care and patient empowerment.
The launch of HeartSecure by Biotricity comes at a strategic time when the home healthcare market is experiencing robust growth. Valued at approximately
For investors, this move indicates Biotricity's intent to capitalize on emerging market trends. The accessibility, affordability and instant results provided by HeartSecure could attract a wide array of consumers, thereby expanding the company’s revenue streams. Additionally, the direct-to-consumer model lowers dependency on traditional healthcare pathways, which are often slow and cumbersome, thus enhancing customer satisfaction and loyalty.
The competitive advantage lies in the proprietary technology and the ease of use, which could make HeartSecure a preferred choice over traditional methods and competitive products. The scalability of direct-to-consumer models also means that Biotricity could roll out similar innovations in other areas of healthcare, further solidifying its market position.
From a financial standpoint, the introduction of HeartSecure has multiple implications for Biotricity. First, this new product is likely to generate additional revenue streams, which is a positive sign for investors. The direct-to-consumer model not only provides higher profit margins but also enhances brand recognition and customer loyalty. Given the projected growth in the home healthcare market, this product launch could contribute significantly to Biotricity's top-line growth.
Cost-efficiency is a important factor here. The reduction in the need for physical appointments and traditional testing methods could lead to lower operating costs and higher profitability. The affordability of HeartSecure also opens up a large addressable market, which could further drive revenue growth.
However, it’s essential to consider the potential risks involved. Market competition is a significant factor and the company must continue to innovate and maintain high-quality standards to stay ahead. Additionally, while the initial launch may attract early adopters, sustained marketing efforts and robust customer support will be necessary to maintain momentum.
Democratizing cardiac health with convenient, rapid, and reliable results
REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announced its groundbreaking direct-to-consumer heart health screening service, HeartSecure, is now available for purchase online at HeartSecure.
Heart disease remains the leading cause of death worldwide, with someone succumbing to cardiovascular disease (CVD) every 1.5 seconds. In the United States alone, 127 million adults have at least one risk factor for heart disease, contributing to one out of every three deaths. Traditional pathways for cardiac screening can involve wait times of up to two months for an appointment and even longer for test results. HeartSecure addresses these delays by providing immediate, at-home results, significantly improving accessibility and timeliness in cardiac care.
Key Benefits of HeartSecure:
Immediate Results: Patients can now receive cardiac screening results instantly, right from the comfort of their own homes.
Accessibility: No more long waits for appointments and results-HeartSecure offers a seamless solution to proactive heart health management.
Affordability: HeartSecure is an affordable option for comprehensive cardiac monitoring.
"At Biotricity, we are committed to leveraging disruptive innovation to enhance lives," says Dr. Waqaas Al-Siddiq, Founder and CEO at Biotricity. " HeartSecure exemplifies our mission by transforming the industry, creating new revenue streams, and delivering significant value to our shareholders. More importantly, it democratizes access to critical cardiac screenings, ultimately saving and improving lives."
HeartSecure stands as a monumental leap in cardiac monitoring, providing unparalleled convenience and peace of mind. By empowering individuals to take control of their cardiac health, Biotricity is reshaping the landscape of heart care. Learn more and purchase HeartSecure online today at HeartSecure.
The home healthcare market, a rapidly growing sector, was valued at approximately
For more information about Biotricity Inc. and its innovative healthcare solutions, please visit Biotricity.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Investor Relations Contacts
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
FAQ
What is HeartSecure?
When was HeartSecure launched?
What are the benefits of HeartSecure?
How does HeartSecure improve cardiac health accessibility?
What is the ticker symbol for Biotricity?
